<DOC>
	<DOCNO>NCT01608087</DOCNO>
	<brief_summary>This trial investigate pharmacokinetics safety BI 695502 establish pharmacokinetic biosimilarity BI 695502 compare bevacizumab .</brief_summary>
	<brief_title>Pharmacokinetics Safety Study BI 695502 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male . 2 . Complete medical history , include physical examination , vital sign , 12lead electrocardiogram ( ECG ) , clinical laboratory test . 3 . Aged 21 50 year . 4 . Body mass index equal 30 . 5 . Body weight 65 95 kg , inclusive . Exclusion criterion : 1 . Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance . 2 . Any evidence clinically relevant concomitant disease , judge investigator . 3 . History relevant orthostatic hypotension , faint spell , blackout . 4 . Chronic relevant acute infection . 5 . History relevant allergy/hypersensitivity ( include allergy study medication excipients ) . 6 . Intake prescribed overthecounter drug within less 6 halflives respective drug prior study drug administration trial . 7 . Participation another trial study medication within two month prior administration trial ( six halflives ) . 8 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) . 9 . Inability refrain smoking day confinement study center . 10 . Current alcohol abuse judge investigator . 11 . Current drug abuse , judge investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>